1,345 reports of this reaction
2.4% of all PANCRELIPASE reports
#7 most reported adverse reaction
VOMITING is the #7 most commonly reported adverse reaction for PANCRELIPASE, manufactured by AbbVie Inc.. There are 1,345 FDA adverse event reports linking PANCRELIPASE to VOMITING. This represents approximately 2.4% of all 56,891 adverse event reports for this drug.
PANCRELIPASE has an overall safety score of 85 out of 100. Patients taking PANCRELIPASE who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for PANCRELIPASE, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for PANCRELIPASE:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 1,345 FDA reports for PANCRELIPASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 2.4% of all adverse event reports for PANCRELIPASE, making it a notable side effect.
If you experience vomiting while taking PANCRELIPASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.